10-Q: Bio-Techne Reports Q3 2025 Results: Sales Up, Earnings Down Due to Arbitration Award

Bio-Techne Corporation reports a 4% increase in net sales but a decrease in net earnings for the third quarter of fiscal year 2025, primarily due to a non-recurring arbitration award.

Summary

• Bio-Techne Corporation's net sales for Q3 2025 increased by 4% to $316.2 million compared to $303.4 million in Q3 2024.
• For the nine months ended March 31, 2025, net sales increased by 6% to $902.7 million compared to $852.9 million in the same period of the prior year.
• Organic revenue increased by 6% for both the quarter and nine-month periods.
• Net earnings for Q3 2025 decreased to $22.6 million from $49.1 million in Q3 2024, primarily due to a non-recurring arbitration award.
• Net earnings for the nine months ended March 31, 2025, decreased to $91.1 million from $127.5 million in the same period of the prior year.
• The company's effective income tax rate for Q3 2025 was 41.0% compared to 19.7% in Q3 2024.
• The company's effective income tax rate for the nine months ended March 31, 2025 was 24.9% compared to 11.5% in the same period of the prior year.
• The company's Protein Sciences segment revenue increased 6% for the quarter and 4% for the nine months ended March 31, 2025.
• The company's Diagnostics and Spatial Biology segment revenue increased 2% for the quarter and 9% for the nine months ended March 31, 2025.
• The company approved a new share repurchase plan authorizing the purchase of up to $500 million of its stock on April 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While sales are up, earnings are down due to a one-time event. The company is taking steps to manage costs and has a new share repurchase plan, but the increased tax rate and global market uncertainties are concerns.

Positives

• Net sales increased by 4% in Q3 2025 and 6% for the nine months ended March 31, 2025.
• Organic revenue growth was 6% for both the quarter and nine-month periods, indicating strong underlying business performance.
• The Protein Sciences and Diagnostics and Spatial Biology segments both experienced revenue growth.
• A new share repurchase plan was approved, potentially boosting shareholder value.

Negatives

• Net earnings decreased significantly in Q3 2025 and for the nine months ended March 31, 2025, primarily due to a non-recurring arbitration award.
• The effective income tax rate increased significantly for both the quarter and nine-month periods.
• Selling, general and administrative expenses increased significantly, impacting profitability.

Risks

• Changing conditions and uncertainty in global markets, including tariffs and trade actions, may adversely affect operations and financial results.
• The full impact of tariffs and other trade actions on the company and its business partners remains highly uncertain and subject to rapid change.
• The company is involved in legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations.

Future Outlook

Management expects to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future through available cash, cash generated from operations, and the existing revolving line of credit.

Management Comments

• The Company's strategic pillars for long-term growth and profitability are to grow and leverage the core, capitalize on high potential markets, market expansion through innovation and acquisition, deliver best-in-class customer experience, and develop people through a transformative culture.

Industry Context

Bio-Techne operates in the biotechnology reagents, instruments, and services market, serving both research and clinical diagnostic sectors. The company's performance is influenced by factors such as pharmaceutical end-market conditions, demand for cell and gene therapy workflow solutions, and the overall health of the life sciences industry.

Comparison to Industry Standards

• It is difficult to provide a direct comparison to industry standards without specific competitor data.
• However, companies like Thermo Fisher Scientific, Danaher Corporation, and Agilent Technologies are major players in similar markets.
• Benchmarking against these companies would require analyzing their revenue growth, profitability, and R&D spending in comparable segments.
• For example, Thermo Fisher Scientific's organic revenue growth in their life sciences solutions segment could be compared to Bio-Techne's organic revenue growth in the Protein Sciences segment.
• Similarly, Danaher's diagnostics segment performance could be compared to Bio-Techne's Diagnostics and Spatial Biology segment.

Legal Proceedings

• The dispute with the former CEO was resolved through a binding arbitration award during the quarter ended March 31, 2025 for which the Company paid $37.2 million inclusive of interest and legal fees.
• The dispute regarding the remaining 12,120 shares was resolved during the quarter resulting in total payments of $0.5 million.

Stakeholder Impact

• Shareholders may be impacted by the decreased net earnings and increased tax rate, but also by the new share repurchase plan.
• Employees may be impacted by restructuring and cost management initiatives.
• Customers may be impacted by potential price increases due to tariffs and trade actions.

Next Steps

• The company will continue to execute its strategic pillars for long-term growth and profitability.
• The company will focus on managing costs and improving operating margins.
• The company will continue to monitor and respond to changing conditions in global markets.
• The company will pay a cash dividend of $0.08 per share on May 30, 2025.

Key Dates

Keywords

Bio-Techne, financial results, Q3 2025, net sales, net earnings, organic revenue, Protein Sciences, Diagnostics and Spatial Biology, share repurchase, arbitration award